Investment in Pharmaceutical Manufacturing in the United Republic of Tanzania

The Government of the United Republic of Tanzania invites qualified local and international investors, consortiums, and strategic partners to submit Expressions of Interest (EOIs) to establishing pharmaceutical manufacturing facilities across the country. This initiative presents a high-impact investment opportunity aimed at expanding domestic pharmaceutical production, securing a reliable supply of essential medicines, accelerating technology transfer and strengthening health care outcomes, fully aligned with Tanzania`s national industrialization and health sector transformation agenda. 

This EOI is issued under the Government`s Green-Lane Approval System and will be implemented through the Pharmaceutical Investment Acceleration Programme (PIAP) a dedicated framework designed to attract, fast-track, and de-risk strategic pharmaceutical investment. Through the Green-Lane mechanism, selected investors will benefit from priority regulatory approvals, accelerated decision making, and coordinated support across government institutions, creating predictable, investor-friendly environment free from unnecessary administrative delays.

This EOI operates on tight timelines, clearly defined deliverables, and rapid turnaround of decision. Submission will be reviewed on a rolling and accelerated basis, with approval granted promptly to investors that demonstrate strong technical capacity, financial strength, and strategic alignment. Investors responding to this call will gain early-mover advantages in a rapidly growing pharmaceutical market with strong government backing and long-term demand fundamentals.